The US Food and Drug Administration (FDA) has announced that it will give drugmakers more time to conduct testing for nitrosamine drug substance-related impurities (NDSRIs) in approved pharmaceuticals if they cannot meet the 1 August 2025, deadline. Manufacturers will need to submit progress reports during this extended period...[FDA]
